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Oedema formation with the vasodilators nifedipine and 
diazoxide: direct local effect or sodium retention?
Henk W. van Hamersvelt, Heinrich J. Kioke, Dirk J. de Jong, 
Robert A.P. Koene and Frans Th.M. Huysmans
Objective To determine whether the common side effect 
of ankle oedema with arteriolar vasodilators such as the 
calcium entry blocker (CEB) nifedipine and the potassium 
channel opener (PCO) diazoxide is the direct result of 
peripheral vasodilation or merely a consequence of renal 
sodium retention.
Design In 12 healthy sitting volunteers we studied for 3 h 
the effects of 20 mg nifedipine, 150 mg diazoxide intra­
venously, 25 mg captopril and placebo on oedema formation 
and sodium excretion.
Conclusions Foot swelling was determined with a new 
accurate device (coefficient of variation 0.30%), which uses 
Archimedes principle to measure water displacement 
induced by immersion of the foot. Blood pressures 
were recorded with a Hawksley random-zero sphygmo­
manometer.
Results All of the active drugs decreased diastolic blood 
pressure (captopril by 9 ±  2°/o, nifedipine by 4 ±  3°/o and 
diazoxide by 2 ±  2%, compared with an increase of 5 ±  2% 
with placebo). Foot volume increased acutely after ad­
ministration of nifedipine (by 2.6 ±  0.4%), whereas it 
remained stable with placebo and the other drugs. 
Administration of captopril and nifedipine induced increases 
of fractional sodium excretion (by 20 +  9% and 40 ±  20%, 
respectively) in contrast to the decreases with placebo and
diazoxide (by 13 +  11% and 24 ±10% , respectively). Only 
administration of nifedipine induced significant, albeit small, 
increases in haemoglobin and serum albumin levels.
Conclusions Administration of nifedipine increased foot 
volume and natriuresis simultaneously, thereby supporting 
the hypothesis that development of ankle oedema with 
CEB is a local phenomenon at the site of vasodilation. The 
absence of a similar increase in foot volume with diazoxide 
administration should be interpreted with caution because 
of the rather minor effect of this dose of diazoxide on blood 
pressure. However, it could be indicative of a different 
mechanism of oedema formation with PCO.
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Introduction
Ankle oedema is a common side effect of antihypertensive 
treatment with arteriolar vasodilators, particularly with 
calcium entry blockers (CEB) and potassium channel 
openers (PCO) such as diazoxide [1]. In the heterogeneous 
group of CEB, the incidence of oedema formation is higher 
with dihydropyridines such as nifedipine than with drugs 
such as verapamil and diltiazem [2]. It is very likely that 
this difference is related to the higher vascular selectivity 
and, consequently, the more pronounced vasodilatory ef­
fect of dihydropyridines [3]. Oedema formation with vaso­
dilating drugs might be a direct result of vasodilation, but 
has also been ascribed primarily to renal sodium retention 
after blood pressure reduction [4]. T he latter possibility 
does not seem to be likely for CEB, which do not cause 
sodium retention [5,6] but even induce acute natriuresis 
and diuresis [7]. To elucidate the mechanism of oedema 
formation, we studied the acute effects of nifedipine,
diazoxide and the angiotensin converting enzyme (ACE) 
inhibitor captopril on foot volume and sodium excretion 
in healthy sitting volunteers.
Methods
Subjects
Twelve healthy volunteers (10 men and two women), aged 
19-33 years, were recruited. All of the participants were 
free of medication and without signs of venous in­
sufficiency. T h e  two women were not using oral con­
traceptives. Blood pressures were below 140/90 mmHg 
(ranges systolic 101-140 and diastolic 60-84) and all of 
the individuals had a normal height (range 167-192 cm) 
and body weight (range 49-95 kg). T h e  study protocol was 
approved by the Sint Radboud Hospital Ethics Committee 
and all of the volunteers gave their written informed 
consent to participate in the study.
1042 Journal of Hypertension 1996, Vol 14 No 8
Fig. 1.
a) foot support 160
257
-hii
J y i
w
C v •  i v T .*  I  «
if VtW?- v.
V » •v ! . ' ;
balance
415
floor
CW8K**i
b)
left
elevated support 
with niche
back
Side view of the foot volume recorder (a) and top view of the immersed bottom 
of foot support (b). Measures of foot support (in millimetres) are indicated by 
the numbers. The Perspex water bath measuring 388 mm x 208 mm x 250 mm 
had a maximal capacity of 201, The left foot of the subject is immersed within 
the water bath and placed on the bottom of the foot support with the heel 
against the niche in the back.
Foot volume recordings
Apparatus and procedure
Like other methods in use for measuring foot volume, our 
method uses the principle of water displacement, but 
records it in a new, indirect and very precise way* As 
shown in Figure la, a Perspex water bath with a maximal 
capacity of 201 is placed on a sensitive electronic balance 
(Mettler PM 34, Mettler Instrumente AG, Greifensee, 
Switzerland). A specially constructed stainless steel foot 
support is suspended in the foot-bath, but rests fully on 
the floor on both sides of the balance. T h e  water bath is 
filled with tap water until the balance indicates exactly 
15 000 g, after which the balance is tared to zero. Sub­
sequent immersion of the foot induces water displacement 
that is perceived by the balance as an increase in weight, 
which equals the immersed volume multiplied by the 
relative weight of water at a specific temperature (0.998 gl 
ml at 22°G). Stated differently, the balance registers the 
force necessary to immerse the foot, which depends solely 
on the volume of the foot (Archimedes principle). In order 
to reach a fixed and reproducible degree of immersion of 
the foot and lower leg, a stable chair with adjustable height 
is used and a rigidly standardized seated position is sought 
with the thigh horizontal, the lower leg vertical and the 
left foot resting on the foot support with the heel against 
the niche in the back and the fore-foot against the left- 
hand side of the foot support (Fig. lb). Moreover, to 
minimize errors caused by different degrees of immersion, 
three or four successive foot placements and recordings 
are performed without actually removing the foot from
are easily corrected for by adding water to the bath until 
the balance again indicates exactly zero. Thus, the same 
water level is attained before each measurement. Because 
the relative volume of water closely approaches unity 
at room temperature (1.00223 ml/g at 22°G), the simple 
conversion of 1 g to 1 ml can be used because it sys­
tematically underestimates volume by only 0.2%.
Testing of the new method
Before studying drug effects, we tested the accuracy of 
the filling of the water bath, the reproducibility of the 
method both for patients and for volunteers and some 
aspects of the biological variation of foot volume.
Study protocol
T h e  acute effects of the experimental drugs on foot 
volume and natriuresis were studied on four different days 
separated by interval periods of at least 3 days. In a 
randomized, cross-over, open manner all subjects received 
oral placebo, 20 mg nifedipine (two 10 mg capsules bitten 
and swallowed), 25 mg captopril (a tablet swallowed) and 
150 mg diazoxide (intravenous infusion during 10 min). 
T h e  volunteers continued their usual diet between ex­
periments.
Subjects were kept fasting during the last 3 h preceding 
the experiments except for an oral water load of 300 ml 
taken 2 h before drug administration. After their arrival at 
the ward, the volunteers were seated in normal office 
chairs with their feet resting on the ground. This sitting 
rest was interrupted only for foot volume recordings and 
for voiding in an adjacent room. After 30 min sitting rest 
by the subject, baseline levels of blood pressure, heart 
rate, body weight and foot volume were recorded and 
baseline blood and urine samples were collected. There­
after, one of the four experimental drugs was administered 
and subjects drank 250 ml tap water. An additional 375 ml 
oral water load was supplied during the next 90 min. Foot 
volumes, body weights, blood pressures and heart rates 
were recorded 30, 60, 120 and 180 min after drug ad­
ministration, whereas blood and urine samples were col­
lected at 60 and 180 min. To reduce the influence of 
biological variation, subjects were always studied at the 
same time of the day and baseline foot volume values 
were recorded after 30 min of sitting rest by the subject. 
Only left foot volumes were recorded.
Blood pressure and heart rate were recorded in triplicate 
with a Hawksley random zero mercury sphygmo­
manometer and by pulse counting, respectively. In blood 
and urine samples, creatinine, sodium and chloride con­
centrations were determined by standard (semi)automated 
the water bath: if fewer than three recordings are within techniques. T h e  haemoglobin level was determined using 
a 5 g range, the foot is withdrawn and the whole procedure a standard automated technique (H3, Technicon, Tarry- 
is repeated. Water losses between experiments caused by town, N ew  York, USA) and the serum albumin level 
removal of the foot from the water bath and evaporation by using an automated bromine cresol green method.
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Table 1 Baseline values before drug administration
Placebo Captopril Diazoxide Nifedipine P
B o d y  weight (kg) 75.3 + 3.8 75.4 + 3.9 75.2 +  3.8 75.1 +3.8 0.09
Systo lic  blood pressure (mmHg) 106 + 3 108 ± 2 104 + 2 105 + 2 0.46
D iasto lic blood pressure (mmHg) 68 ±2 72 ±2 68 ±1 70 + 2 0.13
H e a rt rate (beats/min) 66 + 2 65 + 2 67 +  2 68 + 2 0.27
F o o t volume (ml) 1344 + 44 1335+42 1335 +  43 1333 ± 42 0.56
Haemoglobin level (mmol/l) 8.4 ± 0.1 8.5 + 0.2 8.5 + 0.2 8.5 + 0.2 0.59
A lbum in level (g/l) 48 ±1 50 ±1 49 ±1 50 + 1 0.24
F E (%) 0.6 ±0.1 0.6+ 0.1 0.5 ±0.1 0.6 ±0.1 0.83
F E a (o/o) 1.3+ 0.1 1.2 ±0.1 1.1 ±0.1 1.2 ±0.2 0.50
Va lues are expressed as means ± SEM. FeNai fractional excretion of sodium; FeCi, fraction excretion of chloride. P-values are for comparison of baseline values by 
repeated-measures analysis of variance.
F ractional sodium and chloride excretions (F E Na and F E cl) 
w e r e  calculated using the formula
FEX =  (UX/PX) X (Pcreal/Ucrcat) X 100%
w i t h  Ux and Px representing the urinary and plasma con­
cen tra tions.
Statistical analysis
S ta tis t ic s  were performed with SAS (Statistical Analysis 
S y s te m )  software (SAS Institute Inc., Cary, North Carolina, 
U S A ). Coefficients of variation for reproducibility were 
ca lcu la ted  by one-way analysis of variance [8]. Repeated- 
m e a su re s  analysis of variance was used to compare baseline 
v a lu e s ,  whereas Wilcoxons rank sum test was used to 
c o m p a re  the effects of the experimental drugs with those 
o f  placebo, Percentage changes from baseline values were 
u s e d  for these pairwise comparisons. P<0.05 was con­
s id e re d  statistically significant. Results are presented as 
m e a n s  ±  SEM.
(PcO.Ol, n =  9). During the course of a usual week day, 
the foot volume of healthy students also increased by
1.2 ± 0 .5 %  (PcO.OS, n =  12).
Drug effects
Two subjects were not able to empty their bladders at the 
requested time on one or more occasions, implying that 
comparisons of fractional excretions should be restricted to 
the remaining 10 subjects. Baseline levels of all measured 
parameters were comparable on the four experimental 
days (Table 1).
In these healthy volunteers, only administration of cap­
topril decreased the systolic blood pressure (by 5 ±  2% 
versus 0 ± 1 %  with placebo, / )<0.05). All of the active 
drugs decreased the diastolic blood pressure, with captopril 
and nifedipine having a clearly more pronounced effect 
(Fig. 2). Administration neither of diazoxide nor of cap-
Results
Accuracy of foot volume recordings
R efilling  the water bath
B e c a u se  the balance is also used to control the filling of 
t h e  water bath, replacing the water induced only minor 
e rro rs :  the recorded volume of a standard measure varied 
o n l y  slightly during 10 fillings of the water bath (coefficient 
o f  variation 0.09%, mean volume 1111 ml).
Fig. 2.
Reproducibility
T h r e e  successive recordings were performed within ap­
proxim ately  5 min in 27 volunteers and 22 patients. Be­
tw e e n  recordings, the foot was withdrawn from the water 
b a t h  and dried carefully. T h e  water lost by removal of the 
f o o t  was replaced before the next recording, as indicated 
earlier. In this test, foot volume recordings proved to be 
l i ig h ly  reproducible in volunteers (coefficient of variation 
0 .32% , mean volume 1234 ml) and also in patients (co­
effic ien t of variation 0.28%, mean volume 1292 ml).
S io  log ical varia tio n
F if te e n  minutes of sedentary rest by the subject cor­
resp o n d ed  to an increase in foot volume by 1.0 ±  0.2%
Diastolic BP
+596 -
0%
-5% -
-10%
-15% -
Foot Volume
o  Placebo
•  Captopril
□  Diazoxide
■ Nifedipine
Time (min)
Relative changes in diastolic blood pressure (BP) and foot volume after 
administration of placebo, 20 mg nifedipine, 25 mg captopril and 150 mg 
intravenous diazoxide. *P<0.05, **P<0.01, versus placebo (Wilcoxons rank 
sum test). Error bars indicate SEM.
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Discussion
With our new, simple and accurate method for recording 
foot volume we could demonstrate that administration of 
the CEB nifedipine acutely increases sodium excretion 
and at the same time induces an increase in foot volume 
in healthy sitting volunteers. T he  increase in foot volume 
thus cannot be ascribed to sodium retention. This indicates 
that administration of nifedipine induces a rapid increase 
of volume in the hanging legs by local changes in the 
peripheral vessels. Our data are thus in accord with ob­
servations in isolated and denervated cat skeletal muscles, 
in which local intra-arterial infusion of different types of 
CEB induced an acute increase of transcapillary fluid 
filtration and interfered with the increase in vascular re­
sistance which normally protects capillaries against an 
orthostatic load [9]. Also in humans, systemic ad­
ministration of a dihydropyridine CEB increased tran- 
scapillary fluid filtration in the forearm [10], which could 
have been caused by an increase in intracapillary hy- 
______________________________________________________  drostatic pressure after preferential dilation of small pre­
capillary arterioles by CEB [11,12]. However, experiments 
in bilaterally nephrectomized rats suggested that di- 
topril had an effect on the heart rate ( — 2 +  2% and hydropyridine CEB increase capillary permeability, be- 
+  1 ± 2 % ,  respectively) whereas nifedipine increased it cause nicardipine induced extravasation of Evans blue dye
a %-
Fractional Sodium Excretion
+30%'
-30*-
Mean relative changes in serum albumin level, foot volume and fractional 
sodium excretion (FENb) after administration of placebo, 20 nifedipine, 25 mg 
captopril and 150 mg intravenous diazoxide. *P<0.05, versus placebo 
(Wilcoxons rank sum test). Error bars indicate SEM.
by 7 ±  3% (1 ±  2% decrease with placebo, P<0,05).
T h e  foot volume remained stable on placebo days and 
was changed neither by captopril nor by diazoxide ad­
ministration (Figs 2, 3). In contrast, the foot volume 
increased rapidly with nifedipine administration and re­
mained increased until the end of the experiment 3 h after 
drug administration (mean increase 2.6 ±  0.4%, 7)<0,01, 
Figs 2, 3). N one of the subjects developed visible oedema 
during this short period.
into skeletal muscle and acutely increased haematocrit 
levels more than it did those of serum protein [13]. How­
ever, our data do not support such an increase in capillary 
permeability because nifedipine induced a larger rise in 
the albumin level than it did of the haematocrit level. It 
is noteworthy that a larger rise in serum albumin level 
corresponds to transudation because the albumin level is 
measured in plasma and that of haematocrit in whole 
blood.
T h e  fractional sodium excretion gradually decreased with 
administration of placebo and diazoxide (Fig* 3). In con­
trast, both captopril and nifedipine administration induced 
an increase in natriuresis. Changes in F E C| paralleled the 
changes in F E Na. Administration of the three active drugs 
changed neither the serum sodium level nor the urine 
volume during the 3 h after drug administration (data not 
shown).
«
T h e  only significant change in body weight was a minimal 
decrease with captopril administration (by 0.1 ±  0.1% ver­
sus a 0.1 ± 0 .1 %  increase with placebo, P<0.05). T he 
haemoglobin level decreased slightly on placebo days (by
1.1 ±0 .6% ) and comparable changes were observed with 
diazoxide and captopril administration (0.4 ±0 .6%  and 
0.1 ± 0 .5%  decreases, respectively). Only nifedipine ad­
ministration induced a significant, albeit small, increase in
Infusion of the PCO diazoxide did not cause an increase 
in foot volume. This difference with nifedipine is rather 
unexpected, because CEB and PCO dilate the same pre­
capillary arterioles [12,14]. It might indicate that different 
mechanisms underlie oedema formation with CEB and 
PCO, but our data do not allow firm conclusions to be 
drawn because the dose of diazoxide used hardly changed 
the blood pressure and did not induce reflex tachycardia. 
It is hence not likely that we attained comparable degrees 
of peripheral vasodilation with nifedipine and diazoxide.
T h e  ACE inhibitor captopril did not change foot volume, 
in accord with the fact that these drugs do not cause 
oedema [15]. ACE inhibitors probably do not increase 
hydrostatic pressure in the capillaries because of pref­
erential dilation of larger arterioles [16].
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Because only the acute effects of these vasodilators were 
studied, we should consider the possibility that their 
chronic effects are quite different. In the case of PCO, 
sodium retention with an increase in body weight and 
oedema formation is frequently observed [4]. In contrast, 
sodium balance studies after initiation [17] or dis­
continuation [18] of CEB treatment indicate a long-term 
reduction in the sodium balance. Thus it is not likely that 
oedema during chronic use of CEB is caused by sodium 
retention. Indeed, we have observed several patients who 
developed oedema during CEB administration and had a 
simultaneous reduction in body weight.
In conclusion, the parallel increases in foot volume and 
sodium excretion with nifedipine treatment support the 
hypothesis that ankle oedema with dihydropyridine CEB is 
a local phenomenon and a direct consequence of peripheral 
vasodilation in the hanging legs. The mechanism of oed­
ema formation with PCO remains to be elucidated.
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